North America Virology Market Analysis, Size, and Share by 2028

The virology market in North America is expected to grow from US$ 1,531.21 million in 2021 to US$ 1,984.33 million by 2028; it is estimated to grow at a CAGR of 3.8% from 2021 to 2028.

The US, Canada, and Mexico are economies in North America. Viral infection is among the leading causes of human chronic diseases. A few viruses, such as human immunodeficiency virus (HIV), flu virus, Zika, Diphtheria, Ebola, SARS-CoV-2 (COVID-19), Polio, and Tetanus (Lockjaw), infect large populations across the world. As virus mutate and evolve continuously, drug resistance become an impending challenge for viral infection management among the human and animals. A virus transmits through various mediums based on its type. For instance, some viruses cause respiratory viral diseases, such as flu, common cold, and respiratory syncytial virus infection, transmits through droplets generated through coughing or sneezing, while some because gastrointestinal viral diseases transmitted through feces contaminated food or water. The novel coronavirus that causes COVID-19 was identified in 2019. The International Committee on Taxonomy of Viruses (ICTV) declared the virus as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) on February 11, 2020, and later WHO named the disease as COVID-19. The virus has undergone mutation a couple of times since its outbreak, which has added to the severity of the COVID-19 pandemic. Therefore, the rising prevalence of viral infections drives the growth of the North America virology market.

North America has experienced a rising number of cases of COVID-19 since its outbreak. The cases are also increasing in countries such as Mexico and Canada in the region. As COVID19 is a novel virus and had no established treatment methods, no vaccines, drugs specific to the virus were not available. Thus, it was a potential opportunity for product innovation and development to the market players operating in the virology-related business. The governments have extensively invested in and promoted vaccine development and prioritized the easy and quick approval process. Regional and international players launch various virus products such as rapid test kits, vaccines, and others. And the large-scale production of these products and rising demand are expected to have a favorable impact on the virology-related market in the region. However, the end-users' panic buying and stocking of the products are expected to cause a loss in terms of product expiry. Thus, such factors are expected to have a negative impact on the related market in the region.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive virology market. The North America virology market is expected to grow at a good CAGR during the forecast period.

North America Virology Market Segmentation

     

North America Virology Market – By Type

• Diagnostic Test
  • DNA Virus Testing
  • RNA Virus Testing
  • Others
• Viral Infection Controlling Techniques
  • Active Prophylaxis
  • Passive Prophylaxis
• Antiviral Therapeutics
  • Virucidal Agents
  • Antiviral Agents
  • Immunomodulators
• Interferons

North America Virology Market – By Application

• Skin and Soft Tissue Infections
• Respiratory Tract Infections
• GI Tract Infections
• Sexually Transmitted Diseases
• Urinary Tract Infections
• Others

North America Virology Market – By End User

• Hospitals
• Diagnostic Laboratories
• Pharmaceutical and Biotechnological Companies
• Research and Academic Institutes

North America Virology Market- By Country

• US
• Canada
• Mexico

North America Virology Market-Companies Mentioned

• Abbott
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc
• Illumina, Inc.
• Johnson and Johnson Services, Inc.
• QIAGEN
• Siemens AG
• Thermo fisher scientific inc.

North America Virology Report Scope